Evidence map›Paper›PMID 36275140›Full record

ArticleRSC advances2022

Cefotaxime incorporated bimetallic silver-selenium nanoparticles: promising antimicrobial synergism, antibiofilm activity, and bacterial membrane leakage reaction mechanism.

Abdelrahman A Elakraa, Salem S Salem, Gharieb S El-Sayyad, Mohamed S Attia

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in RSC advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
6.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 75 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Recent Insights into Nanotechnology in Colorectal Cancer.Applied biochemistry and biotechnology · 2024
    Review
  7. Article
  8. Green synthesis of Ag, Se, and AgFolia microbiologica · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Abdelrahman A ElakraaBotany and Microbiology Department, Faculty of Science, Al-Azhar University Nasr City Cairo 11884 Egypt salemsalahsalem@azhar.edu.eg.
Salem S SalemBotany and Microbiology Department, Faculty of Science, Al-Azhar University Nasr City Cairo 11884 Egypt salemsalahsalem@azhar.edu.eg.ORCID https://orcid.org/0000-0003-2898-6708
Gharieb S El-SayyadDepartment of Microbiology and Immunology, Faculty of Pharmacy, Galala University New Galala City, Suez Egypt Gharieb.Elsayyad@gu.edu.eg Gharieb.S.Elsayyad@eaea.org.eg.ORCID https://orcid.org/0000-0001-5410-7936
Mohamed S AttiaBotany and Microbiology Department, Faculty of Science, Al-Azhar University Nasr City Cairo 11884 Egypt salemsalahsalem@azhar.edu.eg.
Al-Azhar University · EGSuez University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this research, we reported for the first time the simple incorporation of antibiotic cefotaxime (CFM) with the synthesized Ag NPs, Se NPs, and bimetallic Ag-Se NPs by gamma rays, as a promising cost-effective, and eco-friendly method. The synthesized nanocomposites were characterized by UV-Vis. spectroscopy, XRD, EDX, HR-TEM, SEM/mapping, and EDX studies. The antimicrobial synergistic potential was investigated after CFM drug incorporation. Antibiofilm activity, growth curve assay, and effect of UV illumination were examined against some pathogenic microbes. The antibacterial reaction mechanism was evaluated by protein leakage assay and SEM imaging. HRTEM imaging confirmed the spherical shape and an average diameter of 10.95, 20.54, and 12.69 nm for Ag NPs, Se NPs, and Ag-Se NPs, respectively. Ag NPs-CFM, Se NPs-CFM, and Ag-Se NPs-CFM possessed antimicrobial activity against

Identifiers

PMID36275140
PMCPMC9486975
OpenAlexW4296503150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.